Semaglutides patent protection in Canada expired in January 2026
10.1681/ASN.20213210S1417b 174 PetrovaB.GulerA
Real-world evidence from observational studies consistently shows that GLP-1 RA use is associated with reduced risk of hepatic decompensation even in patients with established cirrhosis, supporting cautious use in this population
These compounds, called antibody-drug conjugates, have shown promise in preclinical and clinical research (Sapra 2013
De Falco L, Sanchez M, Silvestri L, Kannengiesser C, Muckenthaler MU, Iolascon A, Gouya L, Camaschella C, Beaumont C